Company Analysis

Akebia Therapeutics, Inc. (AKBA)

Nasdaq: AKBA · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2011
Grade5.3
◀ Past 4.2● Present 5.7▶ Future 6.0

Who runs Akebia Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Butler John P.
CEO and President. First filing Mar 2014, latest Aug 10, 2026, 13 filings in all.
Officers reporting now
6
of 13 people with a filing in the last fifteen months
Directors reporting now
7
35 people on the record since 2014
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Butler John P.CEO and PresidentMar 2014Aug 10, 20264 · $500,000
Ostrowski ErikSVP, CFO, CBO & TreasurerJun 2024Jul 1, 20262 · $100,000
Burke Steven KeithSVP, Chief Medical OfficerAug 2019Feb 4, 20263 · $100,000
Grund NicholasChief Commercial OfficerJan 2024Feb 4, 20262 · $100,000
Malabre Richard CSVP, Chief Accounting OfficerJan 2024Feb 4, 20262 · $100,000
Rucci Carolyn M.SVP, Chief Legal OfficerJan 2026Feb 4, 20263 · $100,000
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Adams AdriandirectorDec 2018Jun 22, 2026none
Frieson RondirectorNov 2021Jun 22, 2026none
Rogers Michael WdirectorDec 2018Jun 22, 2026none
Smith CynthiadirectorAug 2018Jun 22, 2026none
Wolf MylesdirectorApr 2020Jun 22, 2026none
Zumwalt Leanne MdirectorFeb 2021Jun 22, 2026none
Vickers Philip J.directorApr 2026Apr 3, 2026none
Earlier names on the record22, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton AKBA · research, not advice